112 related articles for article (PubMed ID: 11529745)
1. Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues.
McMorris TC; Yu J; Lira R; Dawe R; MacDonald JR; Waters SJ; Estes LA; Kelner MJ
J Org Chem; 2001 Sep; 66(18):6158-63. PubMed ID: 11529745
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of enantiomers of antitumor irofulven.
McMorris TC; Staake MD; Kelner MJ
J Org Chem; 2004 Feb; 69(3):619-23. PubMed ID: 14750783
[TBL] [Abstract][Full Text] [Related]
3. Reaction of irofulven with zinc and acid.
McMorris TC; Moon SS; Kelner MJ
J Nat Prod; 2003 Feb; 66(2):310-2. PubMed ID: 12608875
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antitumor activity of amine analogs of irofulven.
McMorris TC; Chimmani R; Gurram M; Staake MD; Kelner MJ
Bioorg Med Chem Lett; 2007 Dec; 17(24):6770-2. PubMed ID: 17977722
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
8. Preparation and biological activity of amino acid and peptide conjugates of antitumor hydroxymethylacylfulvene.
McMorris TC; Yu J; Ngo HT; Wang H; Kelner MJ
J Med Chem; 2000 Sep; 43(19):3577-80. PubMed ID: 11000013
[TBL] [Abstract][Full Text] [Related]
9. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
Van Laar ES; Roth S; Weitman S; MacDonald JR; Waters SJ
Anticancer Res; 2004; 24(1):59-65. PubMed ID: 15015576
[TBL] [Abstract][Full Text] [Related]
10. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
11. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
Wang W; Waters SJ; MacDonald JR; Roth C; Shentu S; Freeman J; Von Hoff DD; Miller AR
Anticancer Res; 2002; 22(2A):559-64. PubMed ID: 12014623
[TBL] [Abstract][Full Text] [Related]
12. (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.
McMorris TC; Kelner MJ; Wang W; Yu J; Estes LA; Taetle R
J Nat Prod; 1996 Sep; 59(9):896-9. PubMed ID: 8864242
[TBL] [Abstract][Full Text] [Related]
13. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies of urea, carbamate, and sulfonamide derivatives of acylfulvene.
McMorris TC; Chimmani R; Alisala K; Staake MD; Banda G; Kelner MJ
J Med Chem; 2010 Feb; 53(3):1109-16. PubMed ID: 20067264
[TBL] [Abstract][Full Text] [Related]
16. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
Wang W; Waters SJ; MacDonald JR; Von Hoff DD; Strodel WE; Miller AR
Anticancer Res; 2001; 21(3B):1789-94. PubMed ID: 11497260
[TBL] [Abstract][Full Text] [Related]
17. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.
Friedman HS; Keir ST; Houghton PJ; Lawless AA; Bigner DD; Waters SJ
Cancer Chemother Pharmacol; 2001 Nov; 48(5):413-6. PubMed ID: 11761460
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
[TBL] [Abstract][Full Text] [Related]
19. Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.
Siegel DS; Piizzi G; Piersanti G; Movassaghi M
J Org Chem; 2009 Dec; 74(24):9292-304. PubMed ID: 19938810
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
Baraldi PG; Balboni G; Pavani MG; Spalluto G; Tabrizi MA; Clercq ED; Balzarini J; Bando T; Sugiyama H; Romagnoli R
J Med Chem; 2001 Aug; 44(16):2536-43. PubMed ID: 11472207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
